Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | IL1RN | P18510 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956375 | 1.00 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL519915 | 0.98 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL12538126 | 0.84 | TSHR (0.60) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL29664081 | 0.84 | TSHR (0.60) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL21813105 | 0.84 | POLB (0.61) | SMN1; SMN2LMNATSHRHTTGAA | |
| SCHEMBL1742543 | 0.81 | USP2 (0.71) | ALDH1A1SMN1; SMN2LMNAHTTGAA | |
| SCHEMBL12674581 | 0.80 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL4555427 | 0.80 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL28308929 | 0.80 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL31684030 | 0.80 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118339145-A | Bicyclic fused ring derivatives or salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-07-12 | — | — | CN | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9546180-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546180-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546180-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9115141-B2 | Substituted isoquinolinones and methods of treatment thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115141-B2 | Substituted isoquinolinones and methods of treatment thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115141-B2 | Substituted isoquinolinones and methods of treatment thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20120245124-A1 | TRPV3 Modulators | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
| EP-2035372-A1 | MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7494994-B2 | Phenylpyridylpiperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-02-24 | — | — | US | disclosed |
| WO-2008005338-A1 | MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20060258670-A1 | New phenylpyridylpiperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-11-16 | — | — | US | disclosed |
| EP-1562961-B1 | HALO SULFONYL ARYL BORONATES | NOVO NORDISK AS (DK) | 2006-10-25 | — | — | EP | disclosed |
| EP-1562961-A1 | HALO SULFONYL ARYL BORONATES | NOVO NORDISK A/S (DK) | 2005-08-17 | — | — | EP | disclosed |
| US-6872849-B2 | Halo sulfonyl aryl boronates | NOVO NORDISK A/S (DK) | 2005-03-29 | — | — | US | disclosed |
| US-20040116701-A1 | Halo sulfonyl aryl boronates | NOVO NORDISK A/S (DK) | 2004-06-17 | — | — | US | disclosed |
| WO-2004041833-A1 | HALO SULFONYL ARYL BORONATES | NOVO NORDISK A/S (DK) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258670-A1 | New phenylpyridylpiperazine compounds | HRH4, HRH3, HRH2 | ALDH1A1 3223/4885SMN1; SMN2 3085/4885LMNA 4719/4885 |
| US-20120245124-A1 | TRPV3 Modulators | TRPV3, TRPV2, TRPV1 | ALDH1A1 3067/4885SMN1; SMN2 2607/4885LMNA 1689/4885 |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | ALDH1A1 3879/4885SMN1; SMN2 1326/4885LMNA 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.